Chen Shanbin, Ou Yangwenshan, Zhao Liang, Li Yang, Qiao Zhenxing, Hao Yanling, Ren Fazheng
Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, China.
Beijing Laboratory for Food Quality and Safety, Beijing, China.
J Neurogastroenterol Motil. 2019 Jan 31;25(1):148-158. doi: 10.5056/jnm17085.
BACKGROUND/AIMS: Probiotics are expected to confer benefits on patients with constipation, but how probiotics act on constipated patients with variable stool consistencies remains unclear. We investigated the effect of strain Shirota (LcS) on constipation-related symptoms, especially stool consistency, of constipated patients.
Constipated patients meeting the Rome III criteria were divided into 3 groups according to the Bristol Stool Form Scale (BSFS): hard (hard stool [HS], BSFS ＜ 3), normal (normal stool [NS], ≤ 3 BSFS ≤ 4), and soft (soft stool [SS], 4 ＜ BSFS ≤ 5) stools. Subjects in each group consumed a probiotic beverage containing 10¹⁰ colony-forming units of LcS daily for 28 days.
LcS intervention significantly alleviated constipation-related symptoms and increased defecation frequency in all subjects. Four weeks of LcS supplementation softened the hard stools in HS, hardened the soft stools in SS, and did not alter the ideal stool consistency in NS. The short-chain fatty acid (SCFA) concentrations were highest in SS, followed by NS and HS. LcS intervention increased the stool SCFA levels in HS but reduced or did not alter the levels in NS and SS. LcS intervention increased the and abundances in HS and decreased the abundance in SS.
LcS supplementation improved the constipation-related symptoms in constipated subjects. Differences in baseline stool consistency could result in different anti-constipation effects of LcS intervention. LcS balanced the stool consistency-softened the HS and hardened the SS. These effects could be associated with modulation of the gut microbiota and SCFA production.
背景/目的：益生菌有望对便秘患者有益，但益生菌如何作用于粪便稠度各异的便秘患者仍不清楚。我们研究了鼠李糖乳杆菌（LcS）对便秘患者便秘相关症状，尤其是粪便稠度的影响。
符合罗马Ⅲ标准的便秘患者根据布里斯托大便分类法（BSFS）分为3组：硬便（硬粪便[HS]，BSFS＜3）、正常便（正常粪便[NS]，3≤BSFS≤4）和软便（软粪便[SS]，4＜BSFS≤5）。每组受试者每天饮用含10¹⁰菌落形成单位LcS的益生菌饮料，持续28天。
LcS干预显著缓解了所有受试者的便秘相关症状，并增加了排便频率。补充LcS四周使HS组的硬便变软，使SS组的软便变硬，而NS组的理想粪便稠度未改变。短链脂肪酸（SCFA）浓度在SS组最高，其次是NS组和HS组。LcS干预使HS组粪便SCFA水平升高，但使NS组和SS组的水平降低或未改变。LcS干预增加了HS组的[具体菌属1]和[具体菌属2]丰度，降低了SS组的[具体菌属3]丰度。
补充LcS改善了便秘受试者的便秘相关症状。基线粪便稠度的差异可能导致LcS干预产生不同的抗便秘效果。LcS平衡了粪便稠度——使HS组变软，使SS组变硬。这些作用可能与肠道微生物群的调节和SCFA的产生有关。
